Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +15

Moderna stock gained 0.57 percent as Nasdaq-100 entry nears

Company update AI-generated analysis

πŸ“ˆ Moderna stock gained 0.57 percent to close at USD 190.01 on October 2, 2026, ahead of its Nasdaq-100 inclusion scheduled for October 9.

πŸ“Š Q2 2026 revenue rose 2.1 percent year-over-year to USD 145 million, while GAAP net loss narrowed to USD 782 million.

πŸ† The Nasdaq-100 entry replaces Warner Bros. Discovery and affects over 200 investment products tracking the major benchmark index.

πŸ“‰ Citi downgraded Moderna from Neutral to Sell on September 30, raising its price target to USD 80.00 despite the positive index news.

🎯 The company reiterated a 2026 revenue-growth outlook of up to 10 percent while continuing investment in vaccines and oncology pipelines.

πŸ“… Moderna will host an investor event on October 24, 2026, linked to data presented at the ESMO Congress.

Bullish Signals
  • Moderna stock gained 0.57 percent as it prepares for Nasdaq-100 inclusion effective October 9, 2026, which places the company in a major benchmark tracked by over 200 investment products.
  • Q2 2026 revenue increased 2.1 percent year-over-year to USD 145 million, demonstrating continued top-line growth despite market headwinds.
  • GAAP net loss narrowed significantly to USD 782 million from USD 825 million in the prior year, with loss per share dropping to USD 1.97.
Risk Factors
  • Citi downgraded Moderna from Neutral to Sell on September 30, 2026, citing a contrast between index inclusion optimism and concerns over current valuation.
Full Analysis
Moderna Inc. stock gained 0.57 percent to close at USD 190.01 on October 2, 2026, as the company prepares for its inclusion in the Nasdaq-100 index effective October 9, 2026. This benchmark status is expected to drive inflows from index-tracking funds, placing Moderna in a major portfolio tracked by over 200 investment products and replacing Warner Bros. Discovery in the index. The biotechnology company reported second-quarter 2026 revenue of USD 145 million, representing a 2.1 percent year-over-year increase from USD 142 million. Concurrently, its GAAP net loss narrowed to USD 782 million from USD 825 million in the prior year, with the loss per share decreasing to USD 1.97 from USD 2.13. Despite the positive index news and revenue growth, analyst sentiment remains mixed with a Hold consensus from 25 analysts. Citi recently downgraded Moderna to Sell while raising its price target to USD 80.00, contrasting with the broader market optimism surrounding the index inclusion and the company's oncology pipeline developments.